Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

NeoStem (NYSE MKT: NBS), Cell Content And Indications Use Patent

Further Expansion of Intellectual Property Coverage

NBS expanded its intellectual property protection around its lead product candidate, AMR-001, with the grant of U.S. patent number 8,343,485 entitled "Compositions and methods of Vascular Injury Repair." This is the 3rd U.S. granted patent for AMR-001, protecting further expansion of its CD34+ chemotactic stem cell product composition claim as well as method CD34+ of sourcing and administration of cells claims.

The Bottom Line: NBS'AMR-001 now enjoys greater protection in terms of its CD34 cell content and the indications for its use, which include treating any vascular injury caused by vascular insufficiency, covering CD34 stem cells sourced from bone marrow or peripheral blood and administered parentally into an artery, vein or muscle. NBS has also 30 additional patents pending around the world.

NBS closed on last Friday, 1/18/13 at $0.62. It is probably an appreciable release but, in this market who knows - my view still worth $0.01 to $0.03 in view of the lack of sector news. AMR-001 now enjoys greater protection in terms of its CD34 cell content.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.